Elitone OTC FDA 510(k) — Pelvic Floor Self-Stimulation. Women's Incontinence 30~40% Blind Spot First OTC Release
BODY

Elitone OTC FDA 510(k) — Pelvic Floor Self-Stimulation. Women's Incontinence 30~40% Blind Spot First OTC Release

By Polly · · Elidah / FDA 510(k)
KO | EN

Urinary incontinence common in women — postpartum·post-menopausal women 30~40%. But treatment rate <20%. Shame·“aging sign” perception·double burden created blind spot. Elidah Elitone 2026.3 FDA 510(k) clearance·2026.4 general sale = first OTC pelvic floor stimulation entry.

Key Announcement

Elitone OTC:

  • FDA 510(k) clearance 2026.3.31
  • OTC (Over-the-Counter) = no prescription
  • Self-use (home daily)
  • Non-invasive (external application)
  • General sale 2026.4
  • Price $399 (US)

Technology:

  • Neuromuscular stimulation (electrotherapy)
  • Photobiostimulation combo
  • External patch (no intravaginal insertion)
  • 20~40 min/day
  • 12-week program

Women’s Incontinence - 30~40% Blind Spot

Prevalence:

  • Post-childbirth women: 35~45%
  • Post-menopausal women: 30~50%
  • 65+ women: 50~60%
  • Korean women estimated 6~8M

Types:

  • Stress (Stress): cough·exercise (60%)
  • Urge: sudden strong urgency (20%)
  • Mixed: both (20%)
  • Overflow: rare

Treatment rate <20% reasons:

  • Shame
  • “Aging sign” acceptance
  • Effect doubt
  • Time·cost
  • Doctor consultation discomfort

Pelvic Floor - Women’s Blind Spot Organ

Structure: Pelvic floor muscles·ligaments, uterus·bladder·rectum support, 4 main muscles (pubococcygeus·iliococcygeus·puborectalis·coccygeus), nerves (pudendal)

Functions: Urine·stool control, sexual function, uterus·bladder support, birth canal

Damage causes: Childbirth (vaginal·abdominal), menopause (estrogen ↓ → muscle·ligament weakness), obesity, chronic constipation·cough, aging

Elitone Mechanism

Electrotherapy: External patch on perineum, low·mid-frequency stimulation, pelvic floor muscle contraction·relaxation, muscle strengthening (8~12 wk)

Photobiostimulation (PBM): Infrared·near-infrared, mitochondrial activation, collagen·muscle recovery, blood flow ↑

Combined effect: Muscle strengthening + tissue recovery, ↑ clinical effect

Clinical Data

12-week RCT (Elidah): Stress incontinence patients, leakage frequency ↓, pad weight test ↓, quality of life improvement (ICIQ-SF), ↓ side effects (transient irritation)

Comparison:

  • Kegel exercise: ↑ effect but ↓ consistency
  • Drugs (Detrol·Vesicare): side effects (dry mouth·drowsiness)
  • Surgery (TVT sling): invasive·cost
  • Elitone: non-invasive + self + OTC

L71 Blind Spot Dimension - Fifth Axis

40 pillar connections:

  • L65 Oura Ring·daily measurement → L71 Elitone daily self-treatment
  • L67 OS-01 senolytic → L71 pelvic floor photobiostimulation
  • L68 RADIESSE decollete → L71 Elitone (each blind spot resolution)

Women urinary·pelvic 5th axis.

Korean Clinical Implications

Current Korea: Kegel education (OB-GYN·physiotherapy), pelvic floor physiotherapy (some clinics), drugs (Detrol·Vesicare insured), surgery (TVT sling) — postpartum some, home pelvic floor devices (Elvie·Perifit)

Elitone expected: US OTC → Korean medical device classification review, Korean MFDS device grade (3rd grade expected), 2027 expected, price $750~$1,500 estimated

Step-by-Step Treatment - Elitone Position

Step 1 - Kegel: Daily 10~15 reps × 3 sets, ↑ effect but ↓ consistency, free, 8~12 wk

Step 2 - Elitone (OTC): Kegel adjunct·enhancement, self-use, 8~12 wk, automated effect

Step 3 - Drug (urge incontinence): Detrol·Vesicare·Myrbetriq, urge-specific

Step 4 - Surgery (severe stress): TVT sling, invasive·cost

Perimenopausal Pelvic Floor - Special Attention

Hormone impact: Estrogen ↓ → pelvic floor muscle·ligament weakness, vaginal·urethral atrophy, collagen ↓, nerve·blood flow ↓

Management: HRT doctor consult, topical estrogen (Vagifem), pelvic floor exercise·stimulation, weight management, diet (water·fiber)

Self-Assessment

Signs: Cough·sneeze·exercise leakage (stress), sudden strong urgency (urge), nocturia, residual urine, sex leakage

Quality of life impact: Exercise avoidance, outing avoidance, pad·diaper dependence, ↓ social activity, depression·self-esteem ↓

Self-Care Guide

Currently possible: Kegel (doctor guidance·apps), pelvic floor physio (OB-GYN referral), weight·diet, drugs (urge incontinence)

Post-Elitone adoption: Home self-use, 12-week program, Kegel + Elitone combo

FAQ

Q. Kegel sufficient alone? A. Mild·early stage = sufficient. Moderate·severe needs Elitone-like stimulation adjunct. ↑ consistency.

Q. Elitone safe? A. Non-invasive external application·FDA 510(k) clearance. ↓ side effects. But bleeding·pregnancy·severe disease = doctor consult.

Q. Buy in Korea? A. US OTC → Korean MFDS device review. 2027 expected. Some overseas direct purchase possible.

Q. Too late post-menopause? A. Not late. Post-menopausal pelvic floor exercise·stimulation still effective. HRT·topical estrogen combo more effective.

Q. Men usable? A. Elitone women-specific. Men’s pelvic floor (prostate·incontinence) = different devices·treatments.

Conclusion

Elitone OTC FDA 510(k) = women incontinence 30~40% blind spot first OTC release. Shame-blocked area now self OTC. L71 = 40 pillars + blind spot dimension (urinary·pelvic 5th axis). Korea 2027 expected. Self-treatment new dimension between Kegel·drug·surgery.

Source: Elidah / FDA 510(k)